SCHEMBL5165358

SCHEMBL5165358

CCOC(=O)c1[nH]nnc1C(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.49
TSHR P16473 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
MAPT P10636 6/20 0.47
LMNA P02545 3/20 0.47
HSD17B2 P37059 1/20 0.47
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46
TUBB8 Q3ZCM7 1/20 0.46
TUBA3E Q6PEY2 1/20 0.46
TUBA1A Q71U36 1/20 0.46
TUBA1C Q9BQE3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5167917 0.92 CYP2C19 (0.50) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL27545274 0.84 TSHR (0.55) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL5517831 0.83 MAPT (0.51) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL5515197 0.80 TSHR (0.54) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL27480820 0.79 TSHR (0.55) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL5648877 0.77 KDM4E (0.46) CYP2C19TSHRCYP1A2CYP2C9MAPT
SCHEMBL5166992 0.77 KMT2A (0.56) CYP2C19CYP1A2CYP2C9MAPTLMNA
SCHEMBL30506315 0.76 HSD17B2 (0.76) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL1660365 0.76 HSD17B2 (0.76) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL5516179 0.72 CYP1A2 (0.43) CYP2C19TSHRCYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1471058-B1 PROCESS FOR PRODUCING 1,2,3-TRIAZOLE COMPOUND MEIJI SEIKA KAISHA (JP) 2007-04-11 EP disclosed
US-20050080270-A1 Process for producing 1 2 3 triazole compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2005-04-14 US disclosed
EP-1471058-A1 PROCESS FOR PRODUCING 1,2,3-TRIAZOLE COMPOUND MEIJI SEIKA KAISHA LTD. (JP) 2004-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080270-A1 Process for producing 1 2 3 triazole compound RPS27L, KARS1, STK38L CYP2C19 30/4885TSHR 718/4885CYP1A2 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.